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Abstract: 
Background: The chronic and debilitating nature of  schizophrenia creates a disease with marked clinical and economic conse-
quences. Smoking in schizophrenia appears to be associated with increased psychopathology and disability. 
Objective: The aim of  this study was to determine if  cigarette smoking in schizophrenia is associated with increased disability 
and psychopathology. 
Materials and methods: This was a cross-sectional descriptive study in which 367 out-patients with International Classification 
of  Diseases (ICD) 10 diagnosis of  schizophrenia were recruited. Socio-demographic questionnaire, Present State Examination 
(PSE) 10, Positive And Negative Syndrome Scale (PANSS) and World Health Organization Disability Assessment Schedule 
(WHODAS) were administered. Data was analyzed using a software package SPSS version 15. 
Results: There was no significant difference in the mean PANSS scores of  smokers and non-smokers. Current smoking was 
associated with increased disability (F=5.39, p=0.02). Total PANSS score significantly predicted disability F(3,71=5.60, p=0.002, 
R2=0.19). There was no significant association between positive or negative symptoms and being a smoker or non-smoker. 
Conclusion: The results of  this study revealed that smoking in Nigerian schizophrenia patients is associated with significant 
disability. Measures should be put in place to discourage cigarette smoking among Nigerian patients with schizophrenia. 
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Introduction
Schizophrenia has been ranked as one of  the ten most 
debilitating diseases worldwide and accounts for 1.1% of  
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the total disability-adjusted life years and 2.8% of  years 
lived with disability1,2.  Studies that compared disabili-
ty across mental disorders showed that schizophrenia 
ranked ahead of  dementia, depression, obsessive com-
pulsive disorder, alcoholism and bipolar affective disor-
der3,4,5. Schizophrenia leads to a breakdown in interper-
sonal and occupational achievement6. Psychopathology 
has been recognized as one of  the most important factors 
in disability7. Disability in schizophrenia persists for years 
after symptom remission8. Disability affects social partic-
ipation mainly and is associated with age of  the patient 
and severity of  psychotic symptoms9.
Nicotine is by far the most prevalent drug abused by 
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schizophrenia patients and it increases mortality rate 
and financial burden incurred in the course of  treat-
ment10,11,12,13.  The effect of  smoking on the outcome of  
schizophrenia has been rather controversial10,13,14,15.
Understanding the effects of  smoking on disability and 
psychopathology in schizophrenia would help develop 
appropriate evidence based biological and psychosocial 
interventions for these patients. No studies investigating 
the influence of  cigarette smoking on the clinical expres-
sion of  schizophrenia as measured via Positive And Neg-
ative Syndrome Scale (PANSS) and disability via World 
Health Organization Disability Assessment Schedule 
(WHODAS) have been reported in the Nigerian South 
East population. This article therefore explored the hy-
pothesis that smoking leads to increased psychopathol-
ogy and disability among patients with schizophrenia in 
South East Nigeria.
Subjects and methods 
This study was carried out at the Federal Neuropsychiat-
ric Hospital located at Enugu, South Eastern region of  
Nigeria. The hospital provides services mainly to patients 
from the five states that make up the South Eastern part 
of  Nigeria. A total of  367 patients with schizophrenia 
from the out-patient department of  the hospital were 
studied.
This was a hospital based descriptive cross-sectional 
study. Three hundred and sixty seven patients with Inter-
national Classification of  Diseases (ICD 10) diagnosis of  
schizophrenia confirmed with Present State Examination 
10 (PSE-10) and not too ill to undergo the interview were 
included in the study. Patients were excluded if  they de-
clined to take part and if  by self  report or from medical 
records it was found that they had any other important 
disorder besides schizophrenia.
WHODAS II 12 Item Version was used to measure dis-
ability. It is a measure of  global disability. The participants 
were asked to rate the level of  difficulty they experienced 
(none 1, mild 2, moderate 3, severe 4, extreme 5), taking 
into consideration the ease in which they performed a 
given activity. Simple sum scoring method was used to 
calculate total disability. The internal consistency and 
test-retest reliability of  the overall WHODAS 2.0 is high. 
WHODAS II has been used previously in Nigeria16,17.
PANSS is a 30-item questionnaire that is used to assess 
patients’ current mental state. The PANSS includes 30 
items on 3 subscales: 7 items covering positive symptoms, 
7 covering negative symptoms and 16 covering general 
psychopathology. Each item is scored on a seven-point 
item-specific Likert scale ranging from 1 to 7. Total Scores 
for the three scales were arrived at by summation of  rat-
ings across the component items. In addition, a compos-
ite scale was scored by subtracting negative from positive 
scores yielding a bipolar index (positive and negative), 
which was essentially a difference in score reflecting the 
degree of  predominance of  one syndrome in relation to 
the other18. Those who had equal scores in both scales 
were regarded as neither positive nor negative. PANSS 
has excellent internal consistency and inter-rater reliabili-
ty. PANSS has been used previously in Nigeria19.
Patients who met the ICD 10 diagnosis of  schizophre-
nia, made by a consultant psychiatrist or a senior trainee 
Psychiatrist (Resident Doctor) were selected. This diag-
nosis was confirmed using the schizophrenia schedule 
of  PSE-10. Thereafter the socio-demographic question-
naire was administered to elicit information about age, 
gender, marital status, educational attainment employ-
ment status and age at onset of  illness. For those who 
accepted ever smoking cigarettes, cigar or pipe in their 
life, PSE-10 smoking schedule was administered. The 
PSE-10 definition of  “ever smoked” was adopted as the 
operational identification of  “life time smoker”, where-
as “current smoking” refered to “having smoked in the 
past four weeks”, irrespective of  frequency or number of  
cigarettes20. Those who smoked 1-10 cigarettes per day 
were classified as light smokers while those who smoked 
more than 10 cigarettes everyday were classified as heavy 
smokers21,22. Early onset schizophrenia was classified as 
schizophrenia with onset before 18 years while late onset 
was above 18 years23.
We measured and quantified the severity of  psychotic 
symptoms of  schizophrenia using Positive and Nega-
tive Syndrome Scale (PANSS) in all the participants. The 
total PANSS Score was recorded. Finally World Health 
Organization Disability Assessment Schedule II 12 item 
version (WHODAS II) was administered to measure dis-
ability in the previous month in all the participants. The 
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participants’ WHODAS scores were dichotomized (yes/
no) such that participants’ with a total score of  12 were 
regarded as having no disability while scores above 12 
indicated presence of  disability24. Daily doses of  neuro-
leptics were converted into chlorpromazine equivalents 
(CPZ-eqs) for ease of  statistical analysis.
Data was cleaned manually and analyzed using Comput-
er software (Statistical Package for the Social Sciences 
Version 15). Statistical testing was conducted at the 5% 
significance level and 95% confidence interval. Gender, 
educational level, age of  the participants, age of  onset 
of  schizophrenia, marital status, religion and employment 
status were presented as simple frequencies and percent-
ages. Chi-square was used to test association between 
symptoms of  schizophrenia and smoking status. PANSS 
score, number of  cigarettes smoked per day, severity of  
smoking and dosage of  anti-psychotic medications were 
entered into a multivariable regression model to adjust 
for confounders and identify predicting associations be-
tween these variables and disability scores. Associations 
between the mean number of  cigarettes smoked per day 
and psychopathology; and between the mean number of  
cigarettes smoked per day and disability were tested using 
t-test.  A p-value <0.05 was considered significant.
This study was approved by the Ethics Committee of  
the Federal Neuropsychiatric Hospital Enugu. Voluntary 
informed consent was sought and obtained from all the 
participants before recruitment into the study.
Results
Table 1 shows the characteristics of  the participants. A 
total of  367 participants were included in the study. Most 
of  the participants, 189 (51.5%) were females. Mean age 
of  the participants was 34.1 ± 9.9 years. Mean age of  
onset of  schizophrenia was 25.3 ± 6.5 years. The mean 
duration of  schizophrenia illness was 8.76 ± 7.54.  Most 
of  the participants, 241 (65.7%) had never been married. 
Most of  the participants had late onset schizophrenia 
(85.3%). One hundred and seventy six (48.0%) of  the 
participants had a predominance of  negative symptoms.
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   Table 1. Socio-demographic and clinical characteristics of participants 
 
Variables  N Percent (%) 
Gender     
Female 189 51.5 
Male 178 48.5 
  
Age (years) 
    
10-29 134   36.5 
30-49 196   53.4 
50-69 37   10.1 
Mean ± S.D 34.1 ± 9.9   
      
Age of onset (years)     
Early onset schizophrenia 54   14.7 
Late onset schizophrenia 313   85.3 
Mean ± S.D 25.3 ± 6.5   
      
Duration of illness (years)     
Mean ± S.D 8.76 ± 7.54   
      
Marital status     
Married 87 23.7 
Never married 241 65.7 
Divorced 32   8.7 
Widowed 7   1.9 
  
Educational level 
    
No formal education 16   4.4 
Primary education 59 16.1 
Secondary education 203 55.3 
Tertiary education 89  24.2 
  
Religion 
    
Christian 364 99.2 
Islam 3   0.8 
  
Employment status 
    
Employed 164 44.7 
Unemployed 203 55.3 
Smoking  status     
Ever smoked 95 25.9 
Currently smokes 75 20.4 
      
Severity of smoking    
    Light smokers 2 2.7 
    Heavy smokers 73 97.3 
 
   Symptoms of schizophrenia 
    
   Predominance of positive symptoms  113 30.7 
   Predominance of negative symptoms 176 48.0 
   Equal dominance 78 21.3 
   Total PANSS Score 45.01±11.89   
 
  Disability 
    
  Yes 313 85.3 
   No 
  
54 14.7 
  Mean disability 22.03 ± 8.35   
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Table 2             Mean WHODAS and PANSS scores among the participants. 
 





WHODAS           
Ever smoked           
  Yes 22.9 8.1 F= 1.52 p=0.22 
  No 21.7 8.4     
            
Currently smokes           
  Yes 24.0 8.1 F= 5.39 p=0.02* 
  No 21.5 8.3     
PANSS           
Ever smoked           
  Yes 44.2 9.5 F=0.6 p= 0.44 
  No 45.3 12.6     
            
Currently smokes           
  Yes 44.8 10.0 F=0.04 p=0.85 
  No 45.1 12.3     
                                                                                                                                                                                           
                                                                     
F=One Way ANOVA    
Table 2 shows that current smokers had a significantly 
higher mean WHODAS score of  24.0 ±8.1 compared 
to 21.5 ±8.3 for those that were not current smokers 
(F= 5.39, p= 0.02).  The current smokers had a higher 
mean disability score (24.0 ±8.1) compared to the life-
time smokers (22.9 ±8.1). Among all the participants 
studied, the mean PANSS score was 45.01±11.89 with 
range 30-94.  There was no significant difference in the 
mean PANSS scores of  those who had never smoked 
and current and lifetime smokers. Multiple regression was 
used to predict disability from Total PANSS score, dosage 
of  antipsychotics and number of  cigarettes smoked per 
day. Total PANSS score significantly predicted disability 
β=0.35, F (3, 71 = 4.16, p=0.00, R2 = 0.19). There was 
a weak positive linear relationship between mean WHO-
DAS Score and total PANSS Score (r=0.43, p= 0.0001) 
and between dosage of  anti-psychotics prescribed and 
number of  cigarettes smoked daily (r=0.27, p=0.009) 
among the current smokers.
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Table 3 Association between smoking, disability and clinical psychopathology 
  
Variable Frequency Percent Stat p-value 
                                                                   Lifetime smoking 
  Yes (%) No (%)     
Predominance of Negative symptoms  50 (52.6) 126 (46.3) X2 =5.72 p=0.06 
Predominance of Positive symptoms 33 (34.8) 80 (29.4) d.f=2   
Equal dominance 12 (12.6) 66 (24.3)     
                                                             Current smoking 
Predominance of Negative symptoms  41 (54.7) 135 (46.2) X2 =4.88 p=0.09 
Predominance of Positive symptoms  25 (33.3) 88 (30.2) d.f=2   
Equal dominance 9 (12.0) 69 (23.6) 
   
Mean No. of cigarettes smoked per day and disability 




Yes 71 (94.7) 3.90 ± 3.62 t= -1.04 p=0.30 
No 4 (5.3) 2.00 ± 0.82     
Mean No. of cigarettes smoked per day and psychopathology 




Predominance of Positive symptoms 25 3.56 ± 3.26 t= -0.73 p=0.47 
Predominance of Negative symptoms  41 4.24 ± 4.23     
 
Table 3 showed greater rate of  smoking among those with 
predominantly negative symptoms. There was no signif-
icant association between number of  cigarettes smoked 
per day, disability scores (t=-1.04, p=0.30) and PANSS 
composite scores (t=-0.73, p=0.47).
 
Discussion
Research regarding the clinical characteristics of  cigarette 
smokers with schizophrenia has produced mixed results, 
which may be attributed to methodological and sampling 
differences25. Reduced rate of  smoking in these patients 
compared to those in developed countries, differing an-
tipsychotic medications, dosage of  anti-psychotics and 
male to female ratio can account for this. A high rate 
of  heavy smoking (97.3%) was found among the partic-
ipants in this study. It was higher than 52% previously 
reported26. This difference can be attributed to variations 
in the cut off  scores for heavy smoking26. Countries, es-
pecially developed countries with higher rate of  smoking 
may tend to use a higher cut off20. 
Most of  the participants (48%) had a predominance of  
negative symptoms. This is higher than 25% and 15.8% 
reported in some other studies27,28. This may be due to 
differences in sampling methods, help seeking behavior, 
duration of  untreated psychosis, long schizophrenia ill-
ness and effect of  medications leading to an increase in 
negative symptoms27,28. Long duration of  untreated psy-
chosis found in developing countries, has been recorded 
among patients with predominantly negative symptoms28.
Current smoking was demonstrated to be significantly as-
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sociated with disability. This is consistent with what has 
been found in some other studies29,30. This has been at-
tributed to smoking being a marker for a more severe 
schizophrenic illness25,31.
There was no significant association between smoking 
status and psychopathology. This is consistent with what 
has been previously reported32. In fact, contrary to what 
was expected, smokers had lesser total clinical psychopa-
thology scores compared to non-smokers. This may be 
due to smoking inducing relaxation and pleasurable feel-
ings and reducing anxiety, anger and depression33. These 
effects may have greater importance among patients with 
schizophrenia because their other sources of  pleasure 
and satisfaction are likely diminished33. This supports 
what has been reported previously that there is little evi-
dence to support that tobacco use worsens the symptoms 
of  schizophrenia14,34.
Smoking status was not significantly associated with 
predominance of  positive or negative symptoms. This 
agrees with reports of  no statistically significant differ-
ences between schizophrenia smokers and non-smokers 
with regard to the severity of  negative symptoms30,35,36. 
Some other studies have reported that patients with more 
severe negative symptoms tend to smoke more to alle-
viate the symptoms of  schizophrenia and that more se-
vere negative symptoms were independently associated 
with current smoking37,38,39. Reduced dopamine neuro-
transmission associated with chronic substance may be 
the cause of  increased negative symptoms among these 
patients10. Clinical psychopathology was independently 
associated with disability among current smokers. This 
supports studies that have reported that though modest, 
increased psychopathology was associated with increased 
disability40. It also agrees with reports of  total PANSS 
and Brief  Psychiatric Rating Scale (BPRS) scores having 
a significant positive correlation with disability13,41.
Limitation
The study was a cross-sectional non-population represen-
tative study with small number of  participants, it included 
only out-patients with schizophrenia, so its results cannot 
easily be generalized to the entire population. Secondly, 
the estimation of  cigarette smoking habits was by self-re-
port. A hundred percent reliability cannot be guaranteed. 
Assessing nicotine dependence with more specific meth-
ods, such as pack- year smoking history and Fagerstrom 
test for nicotine dependence is required in further studies.
Conclusion
Smoking in Nigerian schizophrenia patients is associat-
ed with significant disability and psychopathology. It calls 
for urgent measures to be implemented to discourage 
smoking among Nigerian patients with schizophrenia.
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